Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
gynäkologie + geburtshilfe
Erschienen in: gynäkologie + geburtshilfe 1/2016

15.02.2016 | Sarkome | Zertifizierte Fortbildung

Uterine Sarkome

Heterogene Malignome erfordern differenzierte Therapiestrategien

verfasst von: Prof. Dr. med. Dominik Denschlag, PD Dr. med. Falk Clemens Thiel, Prof. Dr. med. Matthias W. Beckmann, Prof. Dr. med. Peter Mallmann

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Seit August 2015 liegt für die Versorgung von Patientinnen mit den prognostisch oft ungünstigen uterinen Sarkomen eine S2k-Leitlinie vor. Sie bildet die Grundlage zur Entscheidungsfindung für die infrage kommenden Therapieoptionen bei den einzelnen Subtypen.
Literatur
1.
Brooks, S.E., et al., Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol, 2004. 93(1): p. 204–8.PubMedCrossRef
2.
Wittekind, C. and H.J. Meyer, TNM-Klassifikation maligner Tumoren. 2010, Weinheim: Wiley-VHC Verlag. 184–187.
3.
Oliva, E., et al., Mesenchymal Tumors of the Uterus, in WHO Classification of Tumours of Female Reproductive Tract, R.J. Kurman, et al., Editors. 2014, IARC Press: Lyon. p. 135–147.
4.
Conklin, C.M. and T.A. Longacre, Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol, 2014. 21(6): p. 383–93.PubMedCrossRef
5.
Fletcher, C.D.M., et al., WHO Classification of Soft Tissue and Bone. 2013, Lyon: IARC Press.
6.
7.
Lopez-Garcia, M.A. and J. Palacios, Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol, 2010. 27(4): p. 274–86.PubMedCrossRef
8.
Park, J.Y., et al., The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol, 2011. 122(2): p. 255–9.PubMedCrossRef
9.
Denschlag, D., et al., Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd, 2015. 75(10): p. 1028–1042.PubMedCentralPubMedCrossRef
10.
Park, J.Y., et al., The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol, 2010. 17(3): p. 861–8.PubMedCrossRef
11.
Nemani, D., et al., Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol, 2008. 111(1): p. 82–8.PubMedCrossRef
12.
Gadducci, A., et al., The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol, 2008. 65(2): p. 129–42.PubMedCrossRef
13.
Garg, G., et al., Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer, 2010. 20(5): p. 888–94.PubMedCrossRef
14.
Tanner, E.J., et al., The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol, 2011. 123(3): p. 548–52.PubMedCrossRef
15.
Wolfson, A.H., et al., A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol, 2007. 107(2): p. 177–85.PubMedCentralPubMedCrossRef
16.
Cantrell, L.A., et al., A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol, 2012. 127(1): p. 22–6.PubMedCrossRef
17.
Reed, N.S., et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer, 2008. 44(6): p. 808–18.PubMedCrossRef
18.
Sutton, G., et al., A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol, 2000. 79(2): p. 147–53.PubMedCrossRef
19.
Galaal, K., et al., Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev, 2013. 2: p. CD006812.PubMed
20.
Homesley, H.D., et al., Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol, 2007. 25(5): p. 526–31.PubMedCrossRef
21.
du Bois, A., et al., Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol, 2006. 17(1): p. 93–6.PubMedCrossRef
22.
Lacour, R.A., et al., A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer, 2011. 21(3): p. 517–22.PubMedCrossRef
23.
Powell, M.A., et al., Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol, 2010. 28(16): p. 2727–31.PubMedCentralPubMedCrossRef
24.
Abeler, V.M., et al., Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology, 2009. 54(3): p. 355–64.PubMedCrossRef
25.
Kapp, D.S., J.Y. Shin, and J.K. Chan, Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer, 2008. 112(4): p. 820–30.PubMedCrossRef
26.
Zaloudek, C.J., M.R. Hendrickson, and R.A. Soslow, Mesenchymal Tumors of the Uterus, in Blaustein’s Pathology of the Female Genital Tract, R.J. Kurman, L. Hedrick Ellenson, and B.M. Ronnett, Editors. 2011, Springer: New York, Dodrecht, Heidelberg, London.
27.
Perri, T., et al., Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer, 2009. 19(2): p. 257–60.PubMedCrossRef
28.
Leitao, M.M., et al., Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol, 2003. 91(1): p. 209–12.PubMedCrossRef
29.
Pautier, P., et al., A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol, 2013. 24(4): p. 1099–104.PubMedCrossRef
30.
Hensley, M.L., et al., Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol, 2009. 112(3): p. 563–7.PubMedCrossRef
31.
Hensley, M.L., et al., Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer, 2013. 119(8): p. 1555–61.PubMedCrossRef
32.
Bernstein-Molho, R., et al., Metastatic uterine leiomyosarcomas: a single-institution experience. Int J Gynecol Cancer, 2010. 20(2): p. 255–60.PubMedCrossRef
33.
Leitao, M.M., et al., Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol, 2002. 87(3): p. 287–94.PubMedCrossRef
34.
Levenback, C., et al., Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol, 1992. 45(2): p. 202–5.PubMedCrossRef
35.
Weiser, M.R., et al., Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg, 2000. 191(2): p. 184–90; discussion 190-1.PubMedCrossRef
36.
Giuntoli, R.L., 2nd, et al., Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol, 2007. 106(1): p. 82–8.PubMedCrossRef
37.
Anraku, M., et al., Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg, 2004. 127(4): p. 1107–12.PubMedCrossRef
38.
Chen, H., et al., Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg, 1998. 2(2): p. 151–5.PubMedCrossRef
39.
Maki, R.G., et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol, 2007. 25(19): p. 2755–63.PubMedCrossRef
40.
Sutton, G., J.A. Blessing, and J.H. Malfetano, Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 1996. 62(2): p. 226–9.PubMedCrossRef
41.
Hensley, M.L., et al., Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 2002. 20(12): p. 2824–31.PubMedCrossRef
42.
Gupta, A.A., et al., Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review. Clin Oncol (R Coll Radiol), 2013. 25(6): p. 346–55.CrossRef
43.
Sutton, G.P., et al., Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol, 1992. 166(2): p. 556–9.PubMedCrossRef
44.
Look, K.Y., et al., Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol, 2004. 92(2): p. 644–7.PubMedCrossRef
45.
Thigpen, T., et al., Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 1996. 63(1): p. 120–2.PubMedCrossRef
46.
Rose, P.G., et al., Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol, 1998. 70(2): p. 267–71.PubMedCrossRef
47.
Miller, D.S., et al., Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol, 2000. 23(4): p. 355–7.PubMedCrossRef
48.
Gallup, D.G., et al., Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol, 2003. 89(1): p. 48–51.PubMedCrossRef
49.
Chew, I. and E. Oliva, Endometrial stromal sarcomas: a review of potential prognostic factors. Adv Anat Pathol, 2010. 17(2): p. 113–21.PubMedCrossRef
50.
Chang, K.L., et al., Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol, 1990. 14(5): p. 415–38.PubMedCrossRef
51.
Barney, B., et al., Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer, 2009. 19(7): p. 1232–8.PubMedCrossRef
52.
Einstein, M.H., et al., Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer, 2008. 18(5): p. 1065–70.PubMedCrossRef
53.
54.
Shah, J.P., et al., Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol, 2008. 112(5): p. 1102–8.PubMedCrossRef
55.
Beck, T.L., et al., Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecol Oncol, 2012. 125(1): p. 141–4.PubMedCrossRef
56.
Bai, H., et al., Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol, 2014. 132(3): p. 654–60.PubMedCrossRef
57.
Amant, F., et al., Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer, 2007. 97(9): p. 1194–9.PubMedCentralPubMedCrossRef
58.
Amant, F., et al., Clinical management of uterine sarcomas. Lancet Oncol, 2009. 10(12): p. 1188–98.PubMedCrossRef
59.
Leath, C.A., 3rd, et al., A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol, 2007. 105(3): p. 630–4.PubMedCrossRef
60.
Sampath, S., et al., The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys, 2010. 76(3): p. 728–34.PubMedCrossRef
61.
Nam, J.H., Surgical treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol, 2011. 25(6): p. 751–60.PubMedCrossRef
62.
Weitmann, H.D., et al., Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys, 2001. 49(3): p. 739–48.PubMedCrossRef
63.
Kortmann, B., et al., Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. Strahlenther Onkol, 2006. 182(6): p. 318–24.PubMedCrossRef
64.
Cheng, X., et al., Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol, 2011. 121(2): p. 323–7.PubMedCrossRef
65.
Dahhan, T., et al., The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol, 2009. 144(1): p. 80–4.PubMedCrossRef
66.
Maluf, F.C., et al., Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol, 2001. 82(2): p. 384–8.PubMedCrossRef
67.
Pink, D., et al., Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol, 2006. 101(3): p. 464–9.PubMedCrossRef
68.
Harter, P., et al., Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. J Clin Oncol, 2011. 29(suppl; abstr 5093).
69.
du Bois, A., et al., Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol, 2007. 107(3): p. 518–25.PubMedCrossRef
70.
Malouf, G.G., et al., Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynaecol Obstet, 2013. 122(1): p. 57–61.PubMedCrossRef
71.
Tanner, E.J., et al., High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol, 2012. 127(1): p. 27–31.PubMedCrossRef
72.
Schick, U., et al., Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys, 2012. 82(5): p. e757–63.PubMedCrossRef
Metadaten
Titel
Uterine Sarkome
Heterogene Malignome erfordern differenzierte Therapiestrategien
verfasst von
Prof. Dr. med. Dominik Denschlag
PD Dr. med. Falk Clemens Thiel
Prof. Dr. med. Matthias W. Beckmann
Prof. Dr. med. Peter Mallmann
Publikationsdatum
15.02.2016
Verlag
Springer Medizin
Schlagwörter
Sarkome
Strahlentherapie
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 1/2016
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-016-0846-8

Weitere Artikel der Ausgabe 1/2016

gynäkologie + geburtshilfe 1/2016 Zur Ausgabe

Literatur kompakt

CDK4/6-Inhibitor: Lichtblick bei resistentem Mammakarzinom

Medizin aktuell

Überlegungen zur evidenzbasierten Medizin

Industrieforum

Präeklampsie: verlässliche Diagnostik mit angiogenen Faktoren

Praxis konkret

Barrierefreie Praxis zahlt sich aus

Medizin aktuell

Kulturelle Kenntnisse verbessern das Arzt-Patienten-Verhältnis

Medizin aktuell

„Der Palliativdienst sollte zur Grundausstattung jedes Krankenhauses gehören.“

Weitere Lesetipps

Systemtherapie des Prostatakarzinoms im hohen Alter

ANZEIGE

Spektrum Dermatologie: Jetzt auch auf medbee – die App für Mediziner*innen

ANZEIGE

Neue Konzepte beim Handekzem

CME: Glioblastom – aktuelle Therapiekonzepte

Versorgung von Menschen mit spastischer Bewegungsstörung nach Schlaganfall

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

Bildnachweise